Literature DB >> 15812463

Creatine kinase MB (CK-MB) in benign paroxysmal vertigo of childhood: a new diagnostic marker.

Peo Rödöö1, Dan Hellberg.   

Abstract

OBJECTIVES: To evaluate the relation between creatine kinase-MB (CK-MB) and benign paroxysmal vertigo in childhood (BPV). STUDY
DESIGN: We prospectively evaluated and followed serum CK-MB in 22 children with BPV diagnosed between 1998 and 2003.
RESULTS: The average age of debut for BPV was 1.7 years, and follow-up time was 2.8 years. The CK-MB values were elevated in all children. CK-MB values were persistently increased (mean, 6.0 microg/L) during the study period and were not related to duration of BPV, time since last attack, or frequency of attacks. CK-MB became normal in 7 children who recovered during the study period. After the initial increased CK-MB value, CK, aspartate aminotransferase, and cardiac troponin I (in 16 children) were measured as markers of muscular disease. CK was slightly increased in 7 (31.8%) and aspartate aminotransferase in 14 (63.6%) of the children. Cardiac troponin I was normal in all children.
CONCLUSIONS: In this study, serum CK-MB levels were associated with BPV. These findings indicate a possible muscular involvement in BPV. Further studies will be needed to determine if CK-MB is useful as a diagnostic test for BPV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812463     DOI: 10.1016/j.jpeds.2004.10.062

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  2 in total

1.  Increased Otolin-1 in Serum as a Potential Biomarker for Idiopathic Benign Paroxysmal Positional Vertigo Episodes.

Authors:  Yunqin Wu; Weiwei Han; Wang Yan; Xiaoxiong Lu; Min Zhou; Li Li; Qiongfeng Guan; Zhenyi Fan
Journal:  Front Neurol       Date:  2020-05-13       Impact factor: 4.003

2.  Recurrent Vertigo of Childhood: Clinical features and prognosis.

Authors:  Konstanze Dunker; Lutz Schnabel; Eva Grill; Filipp Maximilian Filippopulos; Doreen Huppert
Journal:  Front Neurol       Date:  2022-09-28       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.